Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Ms. Renee Aguiar-Lucander

Market Cap

461.04 Million USD

Sector

Healthcare

Website

https://www.calliditas.se

Description

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

Read More

Overview

Value

1

Growth

12

Health

66

Management

19

Analyst Opinion

71

Total

32

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Has a history of share buybacks
  • Has strong financial health
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • 0
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • 0

Market Peers

CALT

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-120.85%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Buy

Share Buybacks

1.16%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined USD is lower than current price ( 17.18 USD)
  • Free-cashflow-yeild of -6.25% is worse than the market average (4.7%)
  • Margin-of-safety of -120.85% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 17.2 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-6.25%

PE/Earnings Growth

N/A

Price/Book

0.60x

Growth

Growth Score

12

  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of 5.76% is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of -15.24% is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

5.76%

Cashflow Growth

-15.24%

Health

Health Score

66

  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow
  • Cashflow is negative
  • 0
  • Has a high level of debt

Altman Z Score

N/A

Piostroski Score

3.00

Debt/Equity

0.95x

Current Assets/Liabilities

4.34x

Free Cashflow/Total Debt

0.32x

Debt/Capital

0.52x

Management

Management Score

19

  • Has a history of returning value to shareholders through stock buybacks
  • Return-on-capital-employed of -0.54% is lower than the market average (10%)
  • Has repurchased shares when overvalued
  • Return-on-equity of -0.49% is lower than the market average (15%)

Average Buybacks/Dilution

1.16%

Recent Buybacks/Dilution

0.78%

5 Year Price Volitility

25.20%

Return On Assets

-0.19%

Return On Capital Employed

-0.54%

Return On Equity

-0.49%

Return On Free Cashflow

3.01%

Return On Investments

-33.52%

Social Sentiment

Social Sentiment Score

23

Twitter Sentiment

N/A

Stocktwits Sentiment

45.00

Analysts

Analyst Opinion

71

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Calliditas Therapeutics AB (publ)

Currency

USD

Beta

1.295182

Vol Avg

11053

Ceo

Ms. Renee Aguiar-Lucander

Cik

0001795579

Cusip

13124Q106

Exchange

NASDAQ Global Select

Full Time Employees

98

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2020-06-05

Address

Kungsbron 1, C8

City

Stockholm

State

Country

SE

Zip

111 22

Phone

46 84 11 30 05

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies